-
STAT News – Biotech3 months agoSTAT+: ACIP conflict is test of Trump’s support for RFK Jr.’s vaccine policy overhaul
WASHINGTON — Federal health officials are weighing how to respond to a court ruling that stalled major parts of health secretary Robert F. Kennedy Jr.’s vaccine...
-
BioPharma Dive – AI / Data3 months agoEarendil Labs, an AI-powered drugmaker, hauls in $787M
The hefty funding will support a U.S.- and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two lucrative partnerships with Sanofi.
-
Endpoints News3 months ago
Top HHS official tamps down expectations on scope of TrumpRx
The lead drug pricing negotiator at the White House said the overarching goal of TrumpRx is to improve price transparency, not to be a large marketplace...
-
BioPharma Dive – AI / Data3 months agoRoche stops work on experimental SMA drug
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not consistently” improving muscle growth and...
-
STAT News – Biotech3 months agoSTAT+: Medicare chief says TrumpRx is meant to be narrow in scope
At yesterday’s STAT Breakthrough Summit East, Medicare chief Chris Klomp offered a tempered view of TrumpRx, and an MSK cell therapy expert warned that China’s more...
-
Endpoints News3 months ago
Sarepta to ask FDA for full approval of exon skipping drugs; Rhythm’s label expansion in rare form of obesity
Plus, news about Gilead, Assembly Biosciences and Pfizer: 📁 Sarepta says FDA open to a filing for full approval of two Duchenne drugs: After a failed...
-
Endpoints News3 months ago
China-rooted AI biotech Earendil Labs raises $787M ahead of possible IPO
The US-headquartered, China-rooted biotech Earendil Labs said it has raised $787 million in private money, a whopping sum to fund an AI platform that has already...
-
Fierce Biotech3 months ago
Oryon shines out of stealth with $21M to fight Parkinson’s disease
When Ron Cohen, M.D., CEO of Oryon Cell Therapies, recently dug into the company’s Parkinson’s disease data, he told Fierce Biotech it “sang” to him. The...
-
STAT News – Biotech3 months agoSTAT+: Up and down the ladder: The latest comings and goings
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send...
-
Endpoints News3 months ago
UK’s NICE revisits Lilly, Eisai Alzheimer’s drugs under new pricing threshold
The UK’s drug watchdog is reconsidering two Alzheimer’s disease medicines after rejecting them for being too expensive. The National Institute for Health and Care Excellence last...
Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins
STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America
